article · ESMO Real World Data and Digital Oncology
Accurate and reproducible assessment of HER2 IHC is essential for the appropriate selection of targeted therapies, especially in HER2 low or ultralow tumors. Yet, interobserver and inter-scanner variability hinder diagnostic consistency. AI could enhance accuracy and reproducibility, but large-scale, real-world evidence across diverse scanners is scarce.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1016/j.esmorw.2025.100316
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
